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Activation of stem cells in hepatic diseases
T. G. Bird, S. Lorenzini, and S. J. Forbes
MRC/University of Edinburgh Centre for Inflammation Research, The Queen’s Medical Research
Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
Abstract
The liver has enormous regenerative capacity. Following acute liver injury, hepatocyte division
regenerates the parenchyma but, if this capacity is overwhelmed during massive or chronic liver
injury, the intrinsic hepatic progenitor cells (HPCs) termed oval cells are activated. These HPCs
are bipotential and can regenerate both biliary epithelia and hepatocytes. Multiple signalling
pathways contribute to the complex mechanism controlling the behaviour of the HPCs. These
signals are delivered primarily by the surrounding microenvironment. During liver disease, stem
cells extrinsic to the liver are activated and bone-marrow-derived cells play a role in the
generation of fibrosis during liver injury and its resolution. Here, we review our current
understanding of the role of stem cells during liver disease and their mechanisms of activation.
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Introduction
Chronic liver disease is common and has severe clinical consequences that arise from the
loss of functional hepatocytes and excessive scar formation. Currently, therapies are
insufficient to treat these disorders effectively. Great interest has therefore been shown in
characterising the regenerative capacity of the liver in order to manipulate this process
therapeutically. The liver has an exceptional regenerative capacity that is now appreciated to
occur both by replication of differentiated hepatocytes and through activation of the
intrahepatic stem cell compartment. Hepatic stem cells are described as facultative as they
only participate in hepatocyte replacement when regeneration by mature hepatocytes is
overwhelmed or impaired. At present, the consensus is that a bipotential hepatic progenitor
cell (HPC) population expands in human liver diseases and a variety of animal models
(Roskams et al. 2003b; Santoni-Rugiu et al. 2005). Stem-cell-directed therapy thus offers the
hope of improving outcomes during chronic liver disease. Unsurprisingly, interest has more
recently turned to delineating the control mechanisms of the HPCs. Together with
indigenous hepatic stem cells, stem cells within the bone marrow (BM) are also activated
during liver disease and play central roles in inflammation and tissue remodelling. Here, we
aim to review critically the evidence for the presence of stem cells within the liver and the
mechanisms of their activation, together with the role of extrahepatic stem cells during liver
disease.
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Somatic stem cells are expected to display certain characteristics: (1) self-renewal, (2)
multipotentiality, (3) transplantability and (4) functional long-term tissue reconstitution.
Stem cells themselves are required to maintain their undifferentiated state while dividing.
Progenitor cells in contrast show a limited ability to self-renew. They comprise distinct
subpopulations with variable lineage potential. Moreover, unlike stem cells, progenitor cells
divide rapidly but cannot be serially transplanted and hence have been named transit
amplifying cells (Shafritz et al. 2006). Activation in the context of stem cells refers to an
expansion of cell number by proliferation combined with differentiation towards different
lineages. HPCs are thought to be bipotential progenitors capable of forming either
hepatocytes or cholangiocytes. In rodents, HPCs have historically been called oval cells
(OCs) because of their histological appearance.
HPC characterisation
HPCs are heterogeneous, consisting of a spectrum of cells ranging from an immature
phenotype to mature cholangiocytes and intermediate hepatocytes. Although markers for the
most immature progenitor cells have not been identified, there are currently a variety of
established markers for constituents of the HPC compartment (Table 1). Many HPC markers
are expressed by mature cholangiocytes and hepatocytes and by embryonic bipotential
hepatoblasts. No universal HPC marker, specific to this compartment, has been identified to
date. This is likely to be a feature of the progressive differentiation of HPCs during which
they vary their marker expression. Currently, there is a genuine requirement for a thorough
understanding of the step-wise marker expression in HPCs akin to that described for the
development of haematopoietic stem cells.
The early HPC markers described to date include c-kit, sca-1, NCAM, spermatogenic
immunoglobulin superfamily (SgIGSF) and multidrug resistance transporters, which denote
a side-population (SP) phenotype. The SP phenotype was originally described in the
haematopoietic system and relates to the ability to efflux the dye Hoechst 33342. It appears
to identify cells with immature characteristics, particularly with regard to hepatic
embryogenesis (Tsuchiya et al. 2005) and carcinogenesis (Chiba et al. 2006). Another
feature of immature cells is the absence of cytokeratin 7 (CK7) expression; CK7 is
expressed as HPCs acquire a mature phenotype (Paku et al. 2005), which is in keeping with
the demonstration of CK7 in the later stages of hepatic organogenesis (Shiojiri et al. 1991).
Alpha-fetoprotein (αFP) is an OC marker that is also expressed during human hepatic
embryogenesis and carcinogenesis. It appears to be present in intermediate ducts (Alpini et
al. 1992) with prolonged expression for over 3 weeks following partial hepatectomy (PH)
with retrorsine treatment (Gordon et al. 2000) and is also expressed by more differentiated
hepatocyte-like cells in rats (Evarts et al. 1989). αFP expression is however notable by its
absence during the OC response in mice (Jelnes et al. 2007).
Mechanisms of hepatic regeneration
The anatomical position of the liver and its physiological role place it in a toxin-rich
environment. As such, it is required to tolerate frequent exposure to toxins. In addition,
persistent insults such as viral disease, immunological or genetic disorders may continually
challenge the liver. Evolutionarily, the liver has adapted to cope well with such insults and
the regenerative capacity of the adult mammalian liver is immense. An injured liver is able
to call upon a two-tier regenerative strategy comprised initially of mature hepatocyte
followed, if need be, by HPCs (Alison 1998; Fig. 1).
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Hepatocyte-mediated regeneration
Normally, the turnover of hepatocytes in the liver is slow with hepatocytes having a life
span of approximately 1 year. Acute liver injury, for example PH, results in rapid and
effective regeneration with hepatocytes undergoing mitosis leading to subsequent restoration
of liver function within two cycles of division (Fausto et al. 2006). This process in pigs has
recently been shown to include telomerase activation (Wege et al. 2007). Naturally, the
question has been raised as to whether hepatocytes themselves function as stem cells.
Landmark transplantation studies in fumarylacetoacetate hydrolase knockout (FAH −/−) and
urokinase-type plasminogen activator (uPA) transgenic mice have demonstrated that
hepatocytes possess a virtually unlimited proliferative potential. They are capable of a least
69 cell divisions and can restore normal architecture and impaired function in the injured
liver (Rhim et al. 1994; Overturf et al. 1997). Furthermore, Grompe and coworkers have
shown, in the FAH−/− mouse, that adult hepatocytes expand clonally (Overturf et al. 1999)
and may be serially transplanted (Overturf et al. 1997). These models however rely on a
strong selection advantage against native hepatocytes. In addition, wild-type hepatocytes
have been suggested to show multipotentiality when transplanted into the livers of
dipeptidyl peptidase IV (DPPIV) knockout mice followed by PH and retrosine treatment.
DPPIV is an exopeptidase expressed on the bile canalicular surface of hepatocytes in
addition to diffuse cytoplasmic expression by bile duct epithelia. Using this model,
Michalopoulos et al. (2005) have shown that transplanted DPPIV+ cells reconstitute bile
ducts following bile duct ligation (BDL); the authors, in their previous work, note however
that this hepatocyte infusion is not entirely pure (Michalopoulos et al. 2001).
Notwithstanding, this study raises the possibility that hepatocytes may, in specific
circumstances, display multipotentiality. Therefore, under certain conditions, hepatocytes
may show many of the characteristics of stem cells. The models demonstrating self-renewal
nervertheless share continual selection pressure for transplanted hepatocytes versus
indigenous epithelia in the context of persistent liver injury. Whether human hepatocytes are
capable of acting as true stem cells remains doubtful.
HPC-mediated regeneration
Rodent HPC models—The first description of candidate hepatic progenitor-like cells was
made in 1937 (Kinosita 1937) with the subsequent naming of OCs in rodents following a
report by Farber in 1956 (Farber 1956). These cells are characteristically ’small ovoid cells
with scant lightly basophilic cytoplasm and pale blue-staining nuclei” and are not seen in the
uninjured mammalian liver. In rodents, a variety of liver injury models have been used to
induce an OC response (for a comprehensive list, see Santoni-Rugiu et al. 2005). PH alone
in the otherwise uninjured rodent results in a regenerative response by the mature epithelial
compartment but not by OCs. Analysis of carcinogenesis models such as 2-N-
acetylaminofluorene (AAF) in combination with PH has demonstrated that the mitogenic
stimulus of the PH may stimulate OCs when hepatocyte-mediated regeneration is inhibited
(Solt and Farber 1976). AAF is converted to an active cytotoxic/mitoinhibitory N-hydroxy
derivative by the cytochromes of mature hepatocytes (Alison 1998). OCs, by virtue of the
low level expression of hepatocytic cytochromes, are resistant to this toxic effect and, as
such, expand following AAF/PH. The carcinogenic alkaloid retrorsine specifically inhibits
hepatocyte proliferation by a similar mechanism (Laconi et al. 1999) and, like AAF, has
been used in combination with the mitogenic stimulus of PH or toxins, such as carbon
tetrachloride (CCl4) and allyl alcohol, to induce an OC response. Diets, such as the
carcinogenic choline-deficient ethionine-supplemented (CDE) diet or the 3,5-
diethoxycarbonlyl-1,4-dihydrocollidine-supplemented (DDC) diet, also stimulate an OC
response and have more recently become increasingly popular models particularly in mice.
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Investigation of OCs has made remarkable progress since the seminal work by Thorgeirsson
and coworkers (Evarts et al. 1987, 1989) who demonstrated that rats treated with AAF
followed by PH (AAF/PH) exhibited OC proliferation beginning in the periportal region. At
later time points in these models, label-retaining basophilic hepatocytes were seen in the
mid-parenchyma suggesting a precursor/product relationship. Further work has shown that
OCs stream into regenerative nodules (Vig et al. 2006). The tracing of tritiated thymidine
transfer from OCs to parenchymal cells in combination with differentiation markers has
revealed the bipotentiality of HPCs, which are able to form either hepatocytes or
cholangiocytes (Evarts et al. 1989; Holic et al. 2000). Indeed, HPCs themselves may express
mature hepatocyte or biliary duct markers such as CK18 or CK19 (see Table 1. Observations
by electron microscopy to study cell ultrastructure have shown a differentiation gradient of
cells from more primitive progenitors to differentiated hepatocytes and cholangiocytes (De
Vos and Desmet 1992; Mandache et al. 2002). This bipotentiality is furthermore
demonstrated by the generation of stable OC lines that are capable of differentiating into
cholangiocyte or hepatocyte-like cells in vitro (Lazaro et al. 1998). In addition, these cells
are also capable of engrafting following transplantation and expanding in the recipient liver
(Faris and Hixson 1989; Yasui et al. 1997). Therefore, HPCs, in rodents at least, appear to
possess the characteristics of progenitor cells, in addition to possessing a variety of markers
implying stem cell function (e.g. c-kit, CD34 and flt3). Meticulous studies in rodents have
demonstrated that OCs are predominantly derived from the terminal ducts, known as the
canals of Hering, in the biliary tree (Saxena et al. 1999; Theise et al. 1999; Paku et al. 2001).
Following activation, these OCs expand, forming ductular structures extending between the
biliary tree and hepatocytes (Paku et al. 2001). This anatomical position at the interface
between the parenchyma and the portal tract mesenchyme is also the site of bipotential
hepatoblasts during hepatic organogenesis. Although differences have been noted (Dudas et
al. 2006), many phenotypic and functional parallels exist between embryonic bipotential
hepatoblasts and adult HPCs (Shafritz et al. 2006).
HPCs in human liver disease—In humans, HPC activation is believed to take the form
of a ductular reaction. This is morphologically and immunohistochemically analogous to the
rodent OC response. The clinical relevance of the HPC reactions is implied by its frequency
in a wide variety of human liver diseases including fulminant hepatic failure, chronic viral
hepatitis, alcoholic disease, non-alcoholic fatty liver disease, immune cholangiopathies and
hereditary liver disorders (Roskams et al. 1991, 2003a, 2003b; Falkowski et al. 2003;
Roskams 2003; Fig. 2). During acute liver injury, HPC regeneration may be seen occurring
synchronously with a degree of hepatocyte replication. The presence of HPC activation
during chronic liver disease however is probably a feature of eventual exhaustion of
hepatocyte proliferation over many years or decades (Wiemann et al. 2002; Marshall et al.
2005). Characteristically, the magnitude of HPC activation corresponds to the severity of
liver fibrosis and inflammation (Lowes et al. 1999; Libbrecht et al. 2000a; Roskams et al.
2003a). In addition, the more aggressive a hepatocellular injury, the higher the proportion of
observed HPCs that resemble intermediate hepatocytes. This implies that an escalating
hepatocyte deficiency promotes a greater degree of differentiation down the progenitor cell/
hepatocyte axis (Roskams et al. 2003b).
Despite the apparently stereotyped HPC response seen across a wide range of human
diseases, there is heterogeneity both between species and injury models (Jelnes et al. 2007).
For example, the expression of αFP, which is characteristically seen in rodent OC reactions,
is rare in the human ductular reaction. Differing characteristics are seen between models; for
instance, the expression of DMBT1 (deleted in malignant brain tumour 1) is seen following
hepatocelluar injury but not during human cholestatic liver disease or following BDL in
rodents (Bisgaard et al. 2002). Consistent with an atypical HPC response in the BDL model,
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dexamethasone does not effect ductule formation following BDL in rats but inhibits OC
activation following AAF/PH (Nagy et al. 1998).
In contrast to observations in rodents, the characteristics of stem cells have not been
demonstrated in human ductular reactions to date. Sequential biopsies taken from patients
have shown HPC proliferation and suggest their differentiation by observing a progressive
increase in intermediate hepatocytes in association with their progressive extension into the
liver lobule over time (Roskams et al. 1991; Demetris et al. 1996; Falkowski et al. 2003).
Proliferating cells have been isolated from human liver capable of hepatocyte-like
differentiation (Herrera et al. 2006). Further characterisation is required however to confirm
these initial observations.
Mechanisms of HPC activation
The mechanisms controlling the HPC response are under intense investigation. In general,
although many of the signals that control liver regeneration in the normal liver (i.e. via
hepatocyte replication) are involved in HPC-mediated regeneration, acute liver injury does
not significantly activate the HPC compartment. The most common context in which the
HPC reaction is seen is when the cell cycle in hepatocyte regeneration is blocked either by
toxins or replicative senescence in rodent models or human disease. Nevertheless, the two
modes of liver regeneration are not entirely mutually exclusive, as HPC and hepatocyte
replication can be observed simultaneously in some injury models (Rosenberg et al. 2000;
Wang et al. 2003). This may simply be a function of the location, duration and/or magnitude
of these specific signals. However, other factors such as cellular environment are likely to be
highly relevant in generating the HPC response. Certainly, the wide range of candidate
signals, with many showing only modest effects, suggests a significant signal redundancy in
HPC control.
Observational studies show a correlation between liver disease severity and the magnitude
of the HPC response (Lowes et al. 1999; Libbrecht et al. 2000a). A central role of
inflammatory cytokines has also been suggested in rodents (Knight et al. 2005a). These
observations are consistent with the dramatic inhibition of OC responses noted upon
treatment with anti-inflammatory agents (Davies et al. 2006; Nagy et al. 1998). In terms of
specific signals, many have been studied directly during HPC activation in vitro and in vivo
(for an overview, see Table 2). Most of these signals are also seen during PH; however, they
often exhibit differences in either the intensity or duration of the signal.
Tumour necrosis factor superfamily
Members of the pro-inflammatory tumour necrosis factor (TNF) superfamily include TNFα
and TWEAK (TNF-like weak induction of apoptosis), both of which appear to play pivotal
roles in HPC activation. While many members of the TNF superfamily, including TNFα and
lymphotoxin (LT), play important roles in both HPC and hepatocyte-mediated regeneration
(Knight and Yeoh 2005; Fausto et al. 2006), TWEAK stands out by demonstrating
differential effects on the mature hepatocyte and progenitor cell compartments (Jakubowski
et al. 2005). TWEAK is upregulated during hepatic injury, both in rodents and in a variety of
human diseases, and mediates pro-proliferative effects directly on OCs via the Fn14 receptor
(Jakubowski et al. 2005). TWEAK is sufficient, although not necessary, to induce a modest
OC response, whereas its inhibition results in an attenuated murine OC response. This
therefore positions TWEAK as arguably the most important intercellular signal inducing the
hepatic HPC response. It is produced predominantly by monocytes, particularly following
interferon-γ (IFNγ) stimulation (Nakayama et al. 2000), and is initially expressed as a
membrane -ound molecule that can also be released in a soluble form. TWEAK activates
nuclear factor kappaB, which is pro-proliferative to OCs (Kirillova et al. 1999); it may also
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play a role in the proliferation of other mesenchymal progenitors (Girgenrath et al. 2006),
including promoting angiogenesis (Jakubowski et al. 2002), and may contribute to hepatic
embryogenesis and carcinogenesis (Kawakita et al. 2005).
TNFα production is increased during chronic human liver disease (Tilg et al. 1992). It is
known to be predominantly produced by macrophages but also by other cells types,
including lymphocytes and fibroblasts (Locksley et al. 2001), and is upregulated during the
rodent OC response (Knight et al. 2000; Akhurst et al. 2005). Cellular activity is mediated
via the TNF R1 and TNF R2 receptors. Administration of TNFα to OC lines in vitro results
in proliferation (Kirillova et al. 1999). Furthermore, TNF R1 knockout mice show a
markedly impaired OC response (Knight et al. 2000). No study to date, including that with
TNFα/LTα knockout mice (Knight and Yeoh 2005), has shown an absolute requirement for
TNFα but all suggest that TNFα is required for an optimal OC response.
LT-α, LT-β and LIGHT are also members of the TNF superfamily and are involved in a
variety of processes including influencing cell survival and proliferation. LT-α, like TNF,
binds TNF R1, which as described previously plays an important role in the control of the
OC response. Its role in HPC activation is suggested but not confirmed by the demonstration
that LT-α/TNFα double-knockout mice develop an attenuated OC response following the
CDE diet (Knight and Yeoh 2005). LT-α may also act in combination with LT-β via the
formation of a heterotrimer (LTα1β2), which is the ligand for a separate receptor; LT-β
receptor (LT-βR). LT-β expression is upregulated during rodent OC activation and during
chronic human liver disease. Both LT-β knockout and LT-βR knockout mice show a
partially impaired OC response (Akhurst et al. 2005). Another ligand for LT-βR called
LIGHT is potentially therefore also involved. LIGHT is predominantly expressed by
lymphocytes (Hansson 2007) and, although its effects on HPCs have not been directly
investigated, it is known to signal to hepatocytes via LT-βR (Lo et al. 2007).
GP130 activators
A variety of cytokines, including interleukin 6 (IL6), oncostatin M (OSM) and leukaemia
inhibitor factor (LIF), act through the gp130 signalling pathway. Following
homodimerisation, gp130 activates the JAK (Janus kinase)/STAT (signal transductor and
activator of transcription) and ERK (extracellular signal-regulated kinase) pathways. STAT3
and its targets are upregulated during the rodent OC response and during human chronic
liver disease (Sanchez et al. 2004; Subrata et al. 2005) and also play an established role in
hepatocyte-mediated regeneration following PH (Fausto et al. 2006).
Aside from TWEAK, gp130 is the only signal demonstrated to date capable of initiating an
OC response alone. This has been revealed in uninjured gp130Y757F mice with constitutively
active gp130 (Subrata et al. 2005). Another of the downstream targets of gp130, viz. the
ERK-1/2 pathway, has been shown by the same investigators to be a negative regulator of
OC expansion. Therefore, gp130 is potentially a key element in the activation and expansion
of hepatic HPCs. IL-6 is the best characterised of the gp130 activators; it is produced by a
variety of cell types including macrophages, fibroblasts and endothelia. Recent studies have
demonstrated that IL-6 is pro-proliferative to the OC response and that IL-6 knockout mice
demonstrate a reduced OC response (Fischer et al. 1997; Knight et al. 2000; Yeoh et al.
2007). Treatment of OC lines with IL-6 results in proliferation and migration (Matthews et
al. 2004; Yeoh et al. 2007). IL-6 signals via the type I cytokine receptor CD126 (IL-6Rα)
together with the signal transducing gp130 homodimer principally activating STAT3 (Yeoh
et al. 2007). IL-6 expression increases in both acute and chronic human disease and rodent
liver injury models (Streetz et al. 2003; Akhurst et al. 2005; Fausto et al. 2006). Thus, IL-6
is a key signal in hepatocyte proliferation but is not in itself capable of inducing an OC
response (Yeoh et al. 2007). The source of IL-6 during liver injury is likely to be activated
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leucocytes, including Kupffer cells and lymphocytes (Streetz et al. 2003); however, IL6
production has also been described from HPCs themselves, raising the possibility of
autocrine stimulation (Matthews et al. 2004).
LIF and OSM both participate in a variety of processes including the regulation of growth
and differentiation. The action of LIF is mediated via the LIF receptor (LIFR), which is
composed of LIFRβ and gp130. Its downstream effect in OCs occurs predominantly via
STAT1 (Kirillova et al. 1999). Both LIF and LIFR are upregulated during the OC reaction in
the rat (Omori et al. 1996) and in human cirrhotic livers, with LIFRβ localising to
proliferating CK7+ intermediate hepatobiliary cells (Znoyko et al. 2005). Although the
effects of LIF on HPC proliferation are not clear, it does have stimulatory effects on other
progenitor cells, including murine haematopoietic progenitors (Metcalf and Gearing 1989).
LIF has also been described to have effects of hepatocyte differentiation. Murine embryonic
bodies when cultured with LIF are maintained in a undifferentiated state but differentiate
into hepatocyte-like cells upon its removal (Chinzei et al. 2002). OSM also activates gp130,
either via its own OSM receptor (OSMRβ) subunit or via LIFR (Heinrich et al. 2003). OSM
influences extrahepatic progenitor cell activity and extracellular matrix (ECM) deposition, in
addition to inducing an acute phase response. It is produced by hepatic macrophages in
humans and is upregulated during both cirrhotic human liver disease (Znoyko et al. 2005)
and the rodent OC reaction (Matthews et al. 2005). Both murine OCs and human
intermediate hepatobiliary cells express OSMRβ, which induces activation of STAT3
(Znoyko et al. 2005; Matthews et al. 2005). OSM has been described to promote the
proliferation and differentiation of fetal hepatoblasts (Kinoshita et al. 1999) and OCs lines
(Yin et al. 1999, 2002), respectively. Conflicting data however have come from an
immortalised p-53-deficient OC line (Matthews et al. 2005). Further investigation is
required to clarify the role of OSM in HPC activation.
Interferon γ
There is strong evidence for a role of the inflammatory cytokine IFNγ in HPC activation. It
is characteristically expressed by T lymphocytes and natural killer cells. Although it also
activates the JAK-STAT pathway, in contrast to many gp130-mediated signals, INFγ
signals predominantly through the STAT1 pathway (Croker et al. 2003). Its role in HPC
activation was initially examined in a transgenic mouse with constitutive hepatic IFNγ
expression by using a serum amyloid P component gene promoter. These mice demonstrated
cords of small cells morphologically similar to OCs in the context of progressive liver
inflammation (Toyonaga et al. 1994). Since then, OCs have been found to possess functional
IFNγ receptors and IFNγ expression has been shown during the OC reaction (Bisgaard et
al. 1999). Varying effects, including proliferation, are seen when IFNγ is administered to
OC lines (Brooling et al. 2005). More consistent effects have been seen during in vivo
manipulation, with reduced OC expansion being seen in IFNγ knockout mice (Akhurst et al.
2005) and IFNγ treatment stimulating an OC response following PH in mice (Brooling et al.
2005). These observations are consistent with the impaired OC response seen in BALB/c
mice that lack Th1 signalling, of which IFNγ is a key component (Knight et al. 2007).
Caution however should be exercised as reduced OC expansion has also been noted in vitro
(Brooling et al. 2005) and IFNγ may have indirect effects upon the OC response via the
inhibition of hepatocyte proliferation (Fausto et al. 2006). IFNγ has been proposed to be a
factor in determining hepatocyte versus HPC-mediated regeneration, although convincing
data to support this hypothesis are lacking.
Type I interferons
The effects of the type 1 interferons (IFNα and IFNβ) on HPCs appear to differ significantly
from that of IFNγ. IFNα signals predominantly through STAT3 in murine liver (Lim et al.
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2006). Analysis of paired human liver biopsies reveals that both successful and unsuccessful
IFNα treatment of hepatitis C virus is associated with a reduced number of HPCs (Lim et al.
2006; Tsamandas et al. 2006). This effect is not reliant on hepatitis C, as IFNα reduces OC
proliferation both in vitro and in vivo in the absence of hepatitis C infection (Lim et al.
2006). Furthermore, IFNα appears to promote differentiation particularly into hepatocyte-
like cells. The effects of IFNβ on HPCs are unknown, although, like IFNα, it impairs
regeneration following PH alone (Wong et al. 1995; Theocharis etal. 1997). Its role in HPC
activation therefore warrants further investigation.
Primary growth factors
The role of hepatocyte growth factor (HGF) in stimulating hepatocyte proliferation in the
primed liver has been well described (Fausto et al. 2006). Like hepatocytes, OCs also
express the HGF receptor c-Met (Hu et al. 1993; Muller et al. 2002). The expression of HGF
is increased following PH/AAF in the rat (Evarts et al. 1993; Hu et al. 1993), as is uPA
(Nagy et al. 1996), which can release HGF stored in its bound form on the ECM. HGF
levels are also increased in the serum of patients with chronic liver disease and of those
experiencing acute injury compared with healthy controls (Shiota et al. 1995). HGF is both
mitogenic to, and promotes the differentiation of, OCs in vivo (Nagy et al. 1996; Hasuike et
al. 2005). This is in concordance with similar effects on embryonic hepatic stem cells
(Suzuki et al. 2003). There is therefore strong evidence for a role of HGF in influencing
HPC behaviour; however, elevations of HGF in the context of PH alone are insufficient to
stimulate HPC expansion.
Transforming growth factor-α (TGFα) and epidermal growth factor (EGF) are structurally
related membrane-bound growth factors that bind the EGF receptor (EGFR) of adjacent
cells, in turn initiating a variety of effects including the upregulation of the EGFR and cell
proliferation (Leahy 2004). Membrane-bound pro-TGFα may also be cleaved to release a
soluble signal capable of autocrine and paracrine signalling. In rodents, TGFα and EGF are
produced predominantly by stellate cells, which are known to line OC ductules (Paku et al.
2001), whereas the EGFR is expressed by OCs (Evarts et al. 1992). TGFα is upregulated
following AAF/PH injury in rodents (Evarts et al. 1993) and both EGF and TGFα localise to
ductular reactions in human chronic liver disease (Hsia et al. 1994; Komuves et al. 2000).
EGF is mitogenic to OCs in vitro suggesting a role of both growth factors in HPC activation.
The fibroblast growth factors (FGFs) are a family of growth factors that bind their FGF
receptors (FGFR) with the aid of heparin sulphate proteoglycans (Pellegrini 2001). FGFs are
involved in hepatic embryogenesis (Jung et al. 1999) and are upregulated in both the rat
AAF/PH model (Marsden et al. 1992) and during human chronic liver disease (Jin-no et al.
1997). Whereas FGFR2 is upregulated in a variety of liver injuries and is expressed by
numerous cell types, FGFR1 in adult rats is upregulated specifically during HPC-inducing
injury and is expressed by OCs (Hu et al. 1995). In keeping with their role in organogenesis,
FGFs induce a hepatocyte-like phenotype in BM-derived “multipotent adult progenitor
cells” in vitro (Schwartz et al. 2002).
Transforming growth factor-β
TGFβ is well known to limit hepatocyte-mediated regeneration by inhibiting hepatocyte
proliferation and inducing apoptosis (Fausto et al. 2006) and is actively expressed by
myofibroblasts following OC-inducing injury (Park and Suh 1999). Active expression of
TGFβ in a transgenic mouse fed on the DDC diet results in a reduced OC response
(Preisegger et al. 1999). Concordantly, TGFβ is inhibitory to OC lines in vitro (Nguyen et
al. 2007), although TGFβ is less inhibitory of mitosis in OCs than in hepatocytes.
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Stem cell factor
Stem cell factor (SCF) acts via the c-kit receptor and has well-described functions including
the promotion of cell survival and the proliferation and differentiation of haematopoietic
progenitor cells. Expression of SCF is increased in the AAF/PH model but not following PH
alone. Its receptor, c-kit, is an established HPC marker. Functional investigation of c-kit by
using a dysfunctional c-kit receptor suggests that SCF is pro-proliferative to OCs in the rat
(Matsusaka et al. 1999). Interestingly, as discussed previously, gp130 and c-kit activation is
regarded as the minimal requirement for the expansion of haematopoietic progenitors
(Fischer et al. 1997) and, therefore, SCF is also potentially a key player in HPC activation.
Connective tissue growth factor
Connective tissue growth factor (CTGF) is a matrix-associated heparin-binding protein that
mediates cell proliferation and differentiation and ECM remodelling in a variety of tissues.
It is regulated by TGFβ and is known to be upregulated both in animal models of HPC
activation (Pi et al. 2005) and human chronic liver disease (Paradis et al. 2001; Gressner et
al. 2006). Inhibition of CTGF during rat OC proliferation results in reduced cellular
proliferation and expression of αFP (Pi et al. 2005).
Stromal-cell-derived factor 1
The chemokine stromal-cell-derived factor 1 (SDF-1) uniquely binds to the CXCR4 receptor
and plays a variety of roles including cell trafficking, proliferation and organogenesis.
CXCR4 is expressed by a variety of progenitor cells and SDF-1 is upregulated during
human chronic liver disease (Terada et al. 2003). There is however some disagreement over
the source of SDF-1 during the hepatic OC response with reports suggesting either
hepatocytic or periportal production (Hatch et al. 2002; Mavier et al. 2004; Zheng et al.
2006). None-the-less, SDF-1 is clearly upregulated following OC-inducing rodent injury.
SDF-1 has been shown to be both pro-proliferative (Pi et al. 2005) and chemotactic (Hatch
et al. 2002) to OCs.
Peroxisome-proliferator-activated receptor γ
Intracellular peroxisome-proliferator-activated receptors (PPAR) may also mediated a
degree of OC control. Their principally described role is in the control of lipid metabolism
in response to binding to fatty acid and eicosanoid ligands. Their pro-proliferative role
during HPC activation is suggested by in vivo and in vitro studies showing that
administration of a PPARγ inhibitor attenuates OC growth (Knight et al. 2005b). This effect
may in part be mediated by prostaglandins, as PPARγ might be activated by prostaglandin
J2 (Forman et al. 1995). Prostaglandin production is inhibited by COX2 inhibitors, which
themselves are known to inhibit the OC reaction (Davies et al. 2006).
Spermatogenic immunoglobulin superfamily
SgIGSF is an intercellular adhesion molecule that can bind either homophilically or
heterophilically; it is expressed on HPCs both in humans and in rodents and appears to
identify an immature phenotype (Ito et al. 2007). Signal inhibition by using a blocking
antibody results in the inhibition of ductular formation in an in vitro model. The report of Ito
et al. (2007) not only highlights this molecule as a potential further addition to the already
complex array of signals mediating OC control, but also emphasises the ongoing nature of
the description of new pathways mediating such control.
Neural input
Fewer intermediate hepatobiliary cells are seen in transplanted graft livers that develop
recurrent disease than in matched liver biopsies taken from untransplanted patients. This
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observation has led to the hypothesis that denervation as result of transplantation directly
affects the HPC response. Expression of both adrenoreceptors and muscarinic receptors
corresponding to the sympathetic and parasympathetic nervous system respectively has been
described on OCs. The inhibition of the sympathetic or parasympathetic nervous systems
either chemically or surgically in rodents results in the expansion or contraction of the HPC
response, respectively (Cassiman et al. 2002; Oben et al. 2003). The mechanism of action of
neurotransmitters on HPCs together with the demonstration that neurons make direct
functional contract with these cells are topics that remain to be investigated.
As discussed above, a variety of signals have been implicated in the activation of HPCs (see
Fig. 3). Many of these signals are known to be delivered by cells that are seen surrounding
the HPC reaction. This raises the hypothesis of there being a specialised niche regulating
HPC behaviour both physiologically and during disease. The ECM plays a key role in other
stem cell niches and is seen surrounding HPCs (Paku et al. 2001); it is therefore also
implicated in forming the hepatic stem cell niche.
Role of extrahepatic stem cell activation during liver disease
Over the last decade, the importance of BM stem cell (BMSC) activation during liver
disease has become apparent. CD34-positive and CD133-positive cells appear to be
upregulated following liver transplantation or PH in the diseased liver (De Silvestro et al.
2004; Gehling et al. 2005; Lemoli et al. 2006). Similarly, cells with haematopoietic stem cell
markers are mobilised following liver injury in rodents (Fujii et al. 2002) and, in this
context, are recruited to the liver (Kollet et al. 2003). There has been considerable interest in
the possibility that the BM contributes to liver parenchymal and non-parenchymal cells.
Furthermore, current data point towards a role in modulating hepatic fibrosis, in addition to
the control of HPC behaviour outlined above.
Hepatic parenchymal regeneration by BM
Work carried out during the last 10 years has made apparent that OCs express a variety of
markers, such as c-kit and sca-1, that had previously been thought of as haematopoietic (see
Table 1; Petersen et al. 2003). Furthermore, BM-derived stem cells have been shown to
differentiate into hepatocyte-like cells in vitro (Yamazaki et al. 2003; Yamada et al. 2006).
When hepatocytes were identified that expressed extrahepatic markers in both rodent
(Petersen et al. 1999) and human liver (Alison et al. 2000; Theise et al. 2000), the exciting
possibility that BM-derived cells were transdifferentiating into hepatocytes was raised.
Examination by using Y chromosome tracking in human liver specimens from either female
patients with a previous BM transplant from male donors, or male patients who had received
a liver transplant from female donors demonstrated that a number (varying from 0%–40%
depending upon the study) of hepatocytes possessed a Y chromosome (Thorgeirsson and
Grisham 2006). The implication was, therefore, that BM-derived cells were crossing lineage
boundaries via transdifferentiation to form hepatocytes. This was investigated in detail in
rodents including the FAH−/− mouse, a model for human hereditary type I tyrosinaemia in
which hepatic injury may be inhibited at will by the administration of a protective chemical
([2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione], NTBC). NTBC prevents
hepatotoxicity by blocking the formation of fumarylacetoacetate. When FAH−/− mice are
given BM and the protection of NTBC is gradually withdrawn, hepatocytes expressing
markers of the transplanted BM are seen to reconstitute the mouse liver (Lagasse et al.
2000). Subsequent work however has convincingly shown that, instead of plasticity,
monocyte-hepatocyte fusion is the mechanism by which BM cells rescue a genetically
deficient phenotype in the FAH−/− mouse (Alvarez-Dolado et al. 2003; Vassilopoulos et al.
2003; Wang et al. 2003b; Camargo et al. 2004; Willenbring et al. 2004). These monocyte-
hepatocyte fusion events are rare but rescue in the FAH−/− model is nevertheless attributable
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to the proliferation of these fusion cells (Wang et al. 2002). This occurs as selective pressure
is applied against native hepatocytes lacking the correcting wild-type genes. In the absence
of such selective pressure, however, significant hepatocytes replacement is rarely seen and,
at most, occurs at a level far below that of native hepatocytes turnover (Yannaki et al. 2005;
Thorgeirsson and Grisham 2006). Despite initial reports that HPCs may be in part BM-
derived (Petersen et al. 1999), more recent studies suggest that this does not occur to any
significant degree (Wang et al. 2003a; Menthena et al. 2004; Vig et al. 2006). OCs from BM
transplanted mice neither express the BM-tracking marker to any significant degree nor
show clustering suggestive of the expansion of BM-derived OCs. Importantly,
transplantation of an OC fraction into the FAH−/− mouse in one study has shown that
transplantable cells are not BM-derived (Wang et al. 2003a). Some ongoing uncertainty
exists in this area, however, as a recent report suggests that the OCs may indeed be BM-
derived (Oh et al. 2007). The study investigated DPPIV+ cells after DPPIV-deficient rats
were transplanted with wild-type BM. AAF/PH was used in these animals to induce an OC
response and resulted in DPPIV+ cells within the liver (Oh et al. 2007). DPPIV is however
not a specific hepatocyte marker and is expressed by sinusoidal endothelia (Koivisto et al.
2001) and T lymphocytes (Vivier et al. 1991).
BM contribution to hepatic non-parenchymal cells
Kupffer cells/macrophages—Although approximately 80% of the liver mass is
comprised of parenchymal epithelial cells, a number of other cell types play a variety of key
physiological roles within the liver. Leucocyte-derived populations remain as resident
monocytes (Kupffer cells), whereas other populations transiently traffic through the liver. At
least a proportion of hepatic Kupffer cells are BM-derived (Abe et al. 2003; Higashiyama et
al. 2007). Kupffer cells have been implicated in a variety of processes during hepatic disease
including inflammation, regeneration, fibrosis and ECM remodelling. Administration of
gadolinium chloride, which inhibits Kupffer cells, prevents the expansion of OCs positive
for muscle pyruvate kinase, in response to BDL in rats (Olynyk et al. 1998). This is
consistent with the intimate spatial relationship between Kupffer cells and OCs (Yin et al.
1999). Similarly, gadolinium chloride treatment is able to reduce fibrosis in thioacetamide-
treated rats (Ide et al. 2005) consistent with the putative role of Kupffer cells and
macrophages in the process of hepatic fibrosis and ECM remodelling. This role has been
corroborated by using an inducible macrophage-specific depletion model in mice during or
following CCl4 injury; this work has demonstrated that both the generation and resolution of
fibrosis are macrophage-dependent (Duffield et al. 2005). The mechanism of tissue
remodelling may include the expression of the matrix-remodelling metalloproteinase
MMP-9 by BM-derived F4/80+ macrophages during the resolution of fibrosis following
CCl4 injury (Higashiyama et al. 2007).
Hepatic stellate cells—Sustained injury occurring in human chronic liver disease is
usually accompanied by progressive fibrosis and potentially by cirrhosis resulting from
excessive deposition of collagen and other components of the ECM. Central to this process
is the population of matrix-secreting myofibroblasts, which, at least in part, are formed
following the activation of hepatic stellate cells (Henderson and Iredale 2007).
Myofibroblasts not only deposit ECM, but also alter its degradation by the expression of
tissue inhibitors of MMP. Investigations in rodent models by using labelled BM
transplantation (Baba et al. 2004; Russo et al. 2006) or human studies following sex mis-
matched liver or BM transplants (Forbes et al. 2004) have shown a significant BM
contribution to populations of both hepatic stellate cells and myofibroblasts and this process
does not appear to occur through cell fusion. Other studies of the BDL model have found
only a small proportion (5%–10%) of collagen-producing cells are BM-derived (Kisseleva et
al. 2006).
Bird et al. Page 11
Cell Tissue Res. Author manuscript; available in PMC 2011 February 06.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Endothelial progenitors—Capillaries extend alongside the smallest branches of the
biliary tree during chronic rejection following liver transplantation, consistent with new
vessel formation paralleling progenitor ductules (Gouw et al. 2006). A least a proportion of
liver sinusoidal cells that expand following liver injury are BM-derived (Gao et al. 2001;
Fujii et al. 2002; Taniguchi et al. 2006). These cells produce a variety of growth factors
including HGF, EGF and TGFα, all of which have been implicated in modulating the HPC
response (Taniguchi et al. 2006).
The BM is therefore able to produce a variety of cells in response to liver injury (Fig. 4).
These various populations described to date orchestrate an assortment of functions during
liver injury. BM-derived cells act as precursors to a variety of non-parenchymal cells. In
doing so, the BM significantly contributes to the deposition, remodelling and resolution of
hepatic fibrosis. The role of the BM in parenchymal cell regeneration appears to be minimal.
Under carefully controlled experimental conditions, the BM can make dramatic
contributions to hepatocyte regeneration, albeit via fusion with pre-existing hepatocytes
rather than by transdifferentiation.
Functions of BM-derived stem cells during human liver disease
To date only a handful of clinical trials have investigated the role of stem cell mobilisation
therapy or stem cell infusion in adults. G-CSF (granulocyte colony-stimulating factor) has
been used to induce haematopoietic stem cell mobilisation to the peripheral blood of patients
with cirrhosis (Gaia et al. 2006). In association with the mobilisation of CD34+ and CD133+
cells, only two out of eight patients showed moderate improvement in liver function. Trials
of cell therapy have included a cohort of patients with liver cancer in whom portal vein
embolisation was used to induce compensatory hypertrophy in the contralateral liver lobe
prior to surgical resection. Thirteen patients underwent portal vein embolisation, six of
whom received an infusion of autologous CD133+ BMSC. This non-randomised trial
demonstrated a marginal but significant increase in liver volume and reduced time to surgery
in patients receiving autologous BMSC infusions (Furst et al. 2007). Another uncontrolled
study in five patients with cirrhosis investigated the effects of autologous CD34+ BMSCs.
Three of these patients showed transient improvements in biochemical markers such as
bilirubin and albumin over the following 2 months (Gordon et al. 2006). A case report has
described clinical improvement following infusion of autologous G-CSF mobilised CD34+
BM cells in a single patient with hepatic failure (Gasbarrini et al. 2006). Autologous
monocyte therapy has also been attempted by using a larger number of unsorted cells
extracted from the BM of cirrhotic patients. In the nine patients receiving BM, an
improvement in the Child-Pugh score was noted with an increase in intrahepatic cell
proliferation in the patients biopsied after treatment (Terai et al. 2006). Despite these
encouraging reports, caution must be exercised. Only one of these trials used controls (non-
randomised) and all were performed in a small number of patients. Engraftment or
colonisation of infused cell was not investigated in any of the studies. Therefore, a
considerable amount of further investigation is required in this area.
HPCs and cancer
A final consideration of the activation of stem cells during liver disease should include their
potential role in carcino-genesis (see the review by Morrison and Alison in this issue).
Chronic activation of HPCs occurs at a time when liver cancer develops. Inhibition of the
rodent HPC response during the long-term CDE diet is associated with a reduction in the
incidence of cancerous lesions (Knight et al. 2000). The occurrence of mixed forms of liver
cancer with features of both hepatocellular carcinoma and cholangiocarcinoma is consistent
with a bipotential HPC origin (Alison 2005; Roskams 2006), as are the similarities in gene
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expression between HCC subtypes and OCs (Lee et al. 2006). Clearly, these observations
have implications for the use of HPC-directed therapies.
Concluding remarks
To date, a great deal has been learnt about stem cell activation, during liver disease, from
experimental studies in well established rodent models. From a clinical perspective, an
understanding of regenerative processes is essential in guiding patient management and for
offering new therapies to harness or augment the impressive capacity of the liver for
regeneration. Stem cells are at the hub of such regeneration in chronic liver disease but also
appear to be involved in fibrogenesis and carcinogenesis within the liver.
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Abbreviations
αFP Alpha-fetoprotein
AAF 2-N-acetylaminofluorene
BDL Bile duct ligation
BM Bone marrow
BMSC Bone marrow stem cell
CCl4 Carbon tetrachloride
CDE Choline-deficient ethionine-supplemented
CK Cytokeratin
CTGF Connective tissue growth factor
DDC 3,5-Diethoxycarbonlyl-1,4-dihydrocollidine-supplemented
DPPIV Dipeptidyl peptidase IV
ECM Extracellular matrix
ERK Extracellular signal-regulated kinase
EGF Epidermal growth factor
FAH −/− Fumarylacetoacetate hydrolase knockout
FGF Fibroblast growth factor
FGFR FGF receptor
G-CSF Granulocyte colony-stimulating factor
HGF Hepatocyte growth factor
HCC Hepatocellular carcinoma
HPC Hepatic progenitor cell
IFN Interferon
IL Interleukin
JAK Janus kinase
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LIF Leukaemia inhibitor factor
LIFR LIF receptor
LT Lymphotoxin
MMP Metalloproteinase
OC Oval cell
OSM Oncostatin M
OSMR OSM receptor
PH Partial hepatectomy
PPAR Peroxisome-proliferator-activated receptor
SCF Stem cell factor
SDF-1 Stromal-cell-derived factor 1
SgIGSF Spermatogenic immunoglobulin superfamily
STAT Signal transductor and activator of transcription
TGF Transforming growth factor
TNF Tumour necrosis factor
TWEAK TNF-like weak induction of apoptosis
uPA Urokinase-type plasminogen activator
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Fig. 1.
Injury of the healthy liver (a) may be repaired in two ways. Either regeneration from the
fully differentiated hepatocyte compartment (brown) is maintained (b) or it is impaired (e).
In the case of maintained hepatocyte proliferation, replacement of damaged hepatocytes is
quickly and efficiently achieved by division of pre-existing hepatocytes (c) resulting in the
restoration of hepatocyte number (d) without expansion of HPCs. If hepatocyte injury
occurs in the context of impaired hepatocyte proliferation (e), then stem cells (grey) located
in the terminal biliary tree (green) are activated leading to the generation of a transit
amplifying compartment (black, f), which spreads into the liver parenchyma (g). These cells
are able to replace damaged hepatocytes, often forming regenerative nodules (h)
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Fig. 2.
Human ductular reaction in a patient with recurrent hepatitis C infection following cadaveric
liver transplantation. a Pre-perfusion biopsy of donor liver prior to both implantation and
hepatitis C infection; note the CK7+ cells in the bile ducts (arrows). b, c Biopsies from the
same liver 1 and 6 months, respectively, after transplantation and hepatitis C infection.
These sections show CK7+ HPCs (arrowheads) extending from the periportal regions into
the parenchyma.
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Fig. 3.
A variety of influence HPC behaviour by modulating mitosis, differentiation and migration
(abbreviations are explained in Table 1 and in the Abbreviations list)
Bird et al. Page 27
Cell Tissue Res. Author manuscript; available in PMC 2011 February 06.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 4.
Overview of HPC activation during liver injury. During hepatic injury, regeneration of
hepatocytes may occur from hepatocytes or by expansion and differentiation of HPCs. Bone
marrow stem cells (BMSC) are also activated forming macrophages, myofibroblasts and
endothelial cells. Macrophages may fuse with hepatocytes. Macrophages and myofibroblasts
also play key roles in both the production and resolution of fibrosis in the liver
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Table 1
Adult HPC markers with representative references
Oval cell marker and abbreviations References
Adult biliary marker
 Cytokeratin 19 (CK19) Bisgaard et al. 1993
 CK7 Paku et al. 2005
 CK14 Bisgaard et al. 1993
 γ-Glutamyl transpeptidase (γGT) Cameron et al. 1978
 Glutathione-S-transferase P (GST-P) Tee et al. 1992
 Muscle pyruvate kinase (MPK) Akhurst et al. 2005
 OV-6 (recognises CK14 and CK19) Bisgaard et al. 1993
 OV1 Sanchez et al. 2004
 A6 Engelhardt et al. 1993
 OC.2 and OC.3 Hixson and Allison 1985
 Connexin 43 Zhang and Thorgeirsson 1994
 CX3Cl1 Yovchev et al. 2007
 CD24 Yovchev et al. 2007
 MUC1 Yovchev et al. 2007
 Deleted in malignant brain tumour
 1 (DMBT1) Bisgaard et al. 2002
Adult hepatocyte markers
 Albumin Tian et al. 1997
 CK8 Libbrecht et al. 2000b
 CK18 Libbrecht et al. 2000b
 α1-Antitrypsin Gauldie et al. 1980
 Hepatocyte nuclear factor 4 (HNF4) Nagy et al. 1994
 HBD.1 Faris et al. 1991
 c-Met Hu et al. 1993
Fetal hepatocyte markers
 α-Fetoprotein (αFP) Evarts et al. 1987
 Delta-like protein (dlk) Yovchev et al. 2007
 Aldolase A and C Lamas et al. 1987
 c-Met Hu et al. 1993
 Cadherin 22 Yovchev et al. 2007
 CD24 Yovchev et al. 2007
 CD44 Kon et al. 2006
Adult haematopoietic markers
 c-kit Fujio et al. 1994
 CXCR4 Zheng et al. 2006
 CD34 Omori et al. 1997
 Sca-1 Petersen et al. 2003
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